GlassScriptPhysician profile
Curt L Massengale
NPI 1992729909
$3,714.86
in general payments reported to CMS, 2019-2025
21 companies · $577 in 2025
The $577 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $312 · 2021: $553 · 2022: $396 · 2023: $517 · 2024: $617 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,710.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $765.27 | 2019-2025 | Simbrinza, Tryptyr, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $603.26 | 2019-2021 | |
| Oyster Point Pharma, INC. | $508.90 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $434.85 | 2021-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $187.86 | 2020-2025 | |
| Kala Pharmaceuticals, INC. | $187.48 | 2020-2022 | |
| Abbvie INC. | $186.25 | 2023-2024 | |
| Harrow Eye, LLC | $171.46 | 2024-2025 | Vevye |
| Allergan, INC. | $125.25 | 2020-2021 | |
| Dompe US, INC. | $125.19 | 2021 | |
| Glaukos Corporation | $100.60 | 2019 | |
| Mallinckrodt Enterprises LLC | $59.67 | 2019 | |
| Bausch & Lomb Americas INC. | $58.14 | 2022-2023 | Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $43.54 | 2023 | |
| Shire North American Group INC | $30.05 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $27.55 | 2024 | Izervay |
| Aerie Pharmaceuticals, INC. | $24.75 | 2021 | |
| Coopervision INC. | $24.53 | 2020-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.11 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $15.09 | 2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Massengale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.